Published • loading... • Updated
Vaccine Offers New Hope Against Incurable Brain Cancer
The small trial showed immune responses in nearly all patients and no progression at six months, researchers said.
- A WashU Medicine-led clinical trial at Siteman Cancer Center found that a personalized DNA-based vaccine for glioblastoma is safe and potentially improves survival outcomes, enrolling nine adult patients recently diagnosed with the aggressive brain cancer.
- Termed a 'cold' tumor, glioblastoma typically hides from the immune system. Study lead author Tanner Johanns noted the Geneos Therapeutics-developed vaccine transforms these into 'hot' tumors susceptible to immune-mediated eradication.
- Two-Thirds of participants had no progression six months after surgery, while two-thirds survived two years, doubling the historical survival rate. The DNA-based platform targets up to 40 cancer proteins specific to each patient's tumor.
- One participant, former nurse Kim, remains recurrence-free nearly five years after joining the trial. She and her husband, Scott, live in Kirkwood, Missouri, and expressed gratitude for receiving specialized care just a 30-minute drive from their home.
- Senior co-author Gavin Dunn at Mass General Brigham Cancer Institute noted that personalized neoantigen-targeting vaccines represent a compelling approach for glioblastoma. Dunn emphasized these programs require integrated teamwork among dedicated researchers.
Insights by Ground AI
31 Articles
31 Articles
A personalized vaccine to treat glioblastoma, an aggressive and incurable brain cancer that affects about four in 100,000 people in the United States, has been shown to be safe and to induce strong and broad-based immune responses that appear to increase relapse-free survival in some patients after surgery, according to an early clinical trial led by researchers at Washington University School of Medicine in St. Louis. The new treatment uses mod…
Coverage Details
Total News Sources31
Leaning Left6Leaning Right4Center10Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 30%
C 50%
R 20%
Factuality
To view factuality data please Upgrade to Premium
